Show simple item record

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

dc.contributor.authorGillison, ML
dc.contributor.authorBlumenschein, G
dc.contributor.authorFayette, J
dc.contributor.authorGuigay, J
dc.contributor.authorColevas, AD
dc.contributor.authorLicitra, L
dc.contributor.authorHarrington, KJ
dc.contributor.authorKasper, S
dc.contributor.authorVokes, EE
dc.contributor.authorEven, C
dc.contributor.authorWorden, F
dc.contributor.authorSaba, NF
dc.contributor.authorIglesias Docampo, LC
dc.contributor.authorHaddad, R
dc.contributor.authorRordorf, T
dc.contributor.authorKiyota, N
dc.contributor.authorTahara, M
dc.contributor.authorMonga, M
dc.contributor.authorLynch, M
dc.contributor.authorLi, L
dc.contributor.authorFerris, RL
dc.date.accessioned2019-01-30T11:40:24Z
dc.date.issued2018-09-01
dc.identifier.citationThe oncologist, 2018, 23 (9), pp. 1079 - 1082
dc.identifier.issn1083-7159
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3036
dc.identifier.eissn1549-490X
dc.identifier.doi10.1634/theoncologist.2017-0674
dc.description.abstractNivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.
dc.formatPrint-Electronic
dc.format.extent1079 - 1082
dc.languageeng
dc.language.isoeng
dc.publisherWILEY
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectHead and Neck Neoplasms
dc.subjectNeoplasm Recurrence, Local
dc.subjectTime Factors
dc.subjectAntineoplastic Agents, Immunological
dc.subjectNivolumab
dc.titleCheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
dc.typeJournal Article
dcterms.dateAccepted2018-03-06
rioxxterms.versionofrecord10.1634/theoncologist.2017-0674
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2018-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfThe oncologist
pubs.issue9
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublished
pubs.volume23
pubs.embargo.termsNot known
icr.researchteamTargeted Therapy
dc.contributor.icrauthorHarrington, Kevin


Files in this item

Thumbnail
Name:
gillison.pdf
Size:
408.7Kb
Format:
PDF
Description:
Accepted version
View/Open

This item appears in the following collection(s)

Show simple item record